Aim: Aim of this retrospective study was to assess whether there is an advantage of treating women with advanced ovarian cancer with chemotherapy before cytoreductive surgery (neoadjuvant chemotherapy (NACT)) compared with conventional treatment where chemotherapy follows maximal cytoreductive surgery. Patients and Methods: Include patients with advanced epithelial ovarian cancer (stage III and IV) who underwent surgery from 2009-2015 with optimal cyto-reductive surgery (R0). Results: The study included 60 patients the mean age for all patients was 53.7 years, a total of 60 patients diagnosed and treated in NCI and Agouza Police hospital in the specified period (2009-2015), with locally advanced epithelial ovarian carcinoma were divided into 2 groups according to the pattern of treatment where 30 patients seemed resectable and primary cytoreductive surgery was carried out (conventional group), and 30 patients seemed unresectable and neoadjuvant chemotherapy (NACT) was given to them followed by interval debulking surgery J Cancer Sci Clin Ther 2020; 4 (1): 056-064 Journal of Cancer Science and Clinical Therapeutics 57 (IDS). On assessment of the survival we compared the whole number of both groups. The median overall survival time was 45.77 months in the conventional group and 49.06 months in the NACT group.
Introduction
Ovarian carcinoma (OC) represents about three percent of cancers, 10 th ranking cancer and fifth leading cause of cancer-related deaths in women, with the most lethal prognosis among gynecologic cancers. Mortality rates are slightly higher for Caucasian women than for African-American women. In 2012, an estimated 22.280 new diagnoses and an estimated 15.500 deaths in the United States; less than 40% of women with OC are cured [1] . In NCI, Cairo University, tumors of the female genital system Surgery with adjuvant chemotherapy is recommended for patients with epithelial ovarian cancer (EOC) stage IC and up. In locally advanced and metastatic EOC either primary surgery or neoadjuvant chemotherapy (NACT) followed by surgery is a reasonable modality [4] . Numerous combination chemotherapy regimens have been shown to produce responses in patients with OC. Since the mid-1990, a chemotherapy combination consisting of the combination of paclitaxel and a platinum compounds has been used [5] .
Optimizing cytoreduction is by leaving minimal or no residual cancer. Interval debulking surgery (IDS) has gained popularity, mainly reducing the volume of residual disease after primary surgery plus chemotherapy or after chemotherapy alone as much as possible. Several trials have tried to validate IDS, the most important trial on NACT is certainly the EORTC55971 trial, constituting the first prospective multicentric trial to evaluate NACT followed by IDS versus primary surgery followed by adjuvant chemotherapy, concluding that neoadjuvant chemotherapy is not inferior to primary surgery [6] . Kehoe et al. 2013 presented the preliminary results of the CHORUS trial, with similar data as the EORTC55971 [7] .
The aim of this study is to assess and evaluate the experience of the National Cancer institute (NCI), Cairo University and Agouza Police hospital (APH), Cairo-Egypt in treating Egyptian women with advanced EOC with NACT before cytoreductive surgery compared with the conventional treatment where chemotherapy follows optimal cytoreductive surgery, regarding the superiority of one treatment modality over the other. 
Patients and Methods

Exclusion criteria
Included all suboptimal (CC2, CC3) surgical cytoreductions, other pathological types of ovarian cancers, recurrent cases, patients with co-morbidities or low performance status which didn't allow the completion of chemotherapy or the performance of surgery, and reluctant patients with irregular or interrupted follow-ups.
Outcome in both groups was studied regarding
 Overall survival (OS) calculated from date of presentation till date of death or last follow-up.
 Disease free survival (DFS) calculated from date of initial treatment till date of relapse or death or last follow-up.
Statistical analysis
Data was analyzed using IBM SPSS advanced statistics version 22 (SPSS Inc., Chicago, IL 
Institutional review board (IRB) approval:
The study only started after the approval of the IRB. No individual patient consent is needed as the study poses no risk of harm to any of the study subjects.
Protection of privacy and confidentiality of patients' information: Data collection and presentation
was anonymous and both privacy and confidentiality were protected to the maximum possible standards.
Results
The mean age of all the patients was 53.7 years ( Table 1 ).
The Patterns of treatment used in both groups regarding the number of cycles and chemotherapeutics used were summarized in Table 2 . Abdominal distension and pain were the most common complaints at presentation;
Laterality is almost the same in both groups. Table 3 summarizes the patients' complaints, Laterality, and complications related to treatment in both groups. 
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Discussion
Epithelial ovarian cancer (EOC) causes more deaths than any other malignancy affecting the female reproductive system, with advanced stages (III -IV) in up to 75% of cases [8] . The EORTC 55971 trial and the CHORUS trial, both indicated that primary chemotherapy optimize cytoreduction, with less postoperative mortality [6, 7] .
Subsequent clinical studies have confirmed these outcome measures and have also concluded that the rate of stoma formation is significantly reduced in those patients having [15] .
In a similar study to ours, a total of 172 patients with stage III or IV EOC were evaluated between 1998 and 2005 were retrospectively reviewed, demonstrated the superiority of platinum and taxane NACT [16] . In our study a total of 60 patients with stage III or IV EOC were evaluated between 2009 and 2015. All patients were submitted to debulking surgery with optimal cytoreduction (CC0, CC1 
Conclusion
Primary chemotherapy followed by interval debulking surgery in select group of patients doesn't appear to worsen the prognosis, but it permits a less aggressive surgery to be performed. Until there is further confirmatory data, NACT should be restricted to those most unlikely to undergo optimal primary surgery or those too medically compromised. Further studies are needed with larger sample size and longer follow-up to assess the surgical morbidity and mortality in both groups and to confirm the advantages and drawbacks of NACT.
